ZA200207919B - Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use. - Google Patents
Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use.Info
- Publication number
- ZA200207919B ZA200207919B ZA200207919A ZA200207919A ZA200207919B ZA 200207919 B ZA200207919 B ZA 200207919B ZA 200207919 A ZA200207919 A ZA 200207919A ZA 200207919 A ZA200207919 A ZA 200207919A ZA 200207919 B ZA200207919 B ZA 200207919B
- Authority
- ZA
- South Africa
- Prior art keywords
- carbon atoms
- alkyl
- groups
- group
- rings
- Prior art date
Links
- 150000003943 catecholamines Chemical class 0.000 title 1
- 150000007925 phenylethylamine derivatives Chemical class 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 6
- 125000000217 alkyl group Chemical group 0.000 abstract 5
- -1 dimethylamino, N-methyl-N-ethylamino Chemical group 0.000 abstract 3
- 208000018737 Parkinson disease Diseases 0.000 abstract 2
- 125000001931 aliphatic group Chemical group 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 2
- 125000001188 haloalkyl group Chemical group 0.000 abstract 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000023105 Huntington disease Diseases 0.000 abstract 1
- 206010020772 Hypertension Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 1
- 125000005418 aryl aryl group Chemical group 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 abstract 1
- 125000004850 cyclobutylmethyl group Chemical group C1(CCC1)C* 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 abstract 1
- 201000001881 impotence Diseases 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/14—Aza-phenalenes, e.g. 1,8-naphthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
- C07C225/14—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
- C07C225/20—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
- C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D211/70—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/08—Aza-anthracenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/06—Ring systems of three rings
- C07D221/10—Aza-phenanthrenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/04—Ortho- or peri-condensed ring systems
- C07D221/18—Ring systems of four or more rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
- C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/04—Ortho- or ortho- and peri-condensed systems containing three rings
- C07C2603/22—Ortho- or ortho- and peri-condensed systems containing three rings containing only six-membered rings
- C07C2603/26—Phenanthrenes; Hydrogenated phenanthrenes
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0001438A SE0001438D0 (sv) | 2000-04-18 | 2000-04-18 | New chemical compounds and their use in therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200207919B true ZA200207919B (en) | 2003-10-02 |
Family
ID=20279367
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200207919A ZA200207919B (en) | 2000-04-18 | 2002-10-02 | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use. |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US6683087B2 (enExample) |
| EP (1) | EP1274411B1 (enExample) |
| JP (1) | JP4819280B2 (enExample) |
| CN (2) | CN100383126C (enExample) |
| AT (1) | ATE300290T1 (enExample) |
| AU (2) | AU2001248982B2 (enExample) |
| CA (1) | CA2406044C (enExample) |
| CZ (1) | CZ20023455A3 (enExample) |
| DE (1) | DE60112269T2 (enExample) |
| DK (1) | DK1274411T3 (enExample) |
| ES (1) | ES2244604T3 (enExample) |
| HU (1) | HU229794B1 (enExample) |
| NZ (1) | NZ521860A (enExample) |
| PL (1) | PL204661B1 (enExample) |
| PT (1) | PT1274411E (enExample) |
| SE (1) | SE0001438D0 (enExample) |
| SI (1) | SI1274411T1 (enExample) |
| WO (1) | WO2001078713A1 (enExample) |
| ZA (1) | ZA200207919B (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2616028A1 (en) * | 2005-07-22 | 2007-02-01 | Sloan-Kettering Institute For Cancer Research | Synthesis of scabronines and analogues thereof |
| US7910623B2 (en) * | 2005-07-22 | 2011-03-22 | Sloan-Kettering Institute For Cancer Research | Synthesis of scabronines and analogues thereof |
| SI1907382T1 (sl) | 2005-07-26 | 2015-10-30 | Bial-Portela & Ca S.A., | Nitrokateholni derivati kot inhibitorji COMT |
| EP1845097A1 (en) * | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| ES2597705T3 (es) | 2007-01-31 | 2017-01-20 | Bial - Portela & Ca., S.A. | Derivados de nitrocatecol como inhibidores de COMT administrados con un régimen de dosificación específico |
| US20090124651A1 (en) | 2007-08-31 | 2009-05-14 | H. Lundbeck A/S | Catecholamine derivatives and prodrugs thereof |
| EP2276758B1 (en) | 2008-03-17 | 2016-01-06 | Bial-Portela & CA, S.A. | Crystal forms of 5- [3- (2, 5-dichloro-4, 6-dimethyl-1-oxy-pyridine-3-yl) [1,2,4] oxadiazol-5-yl]-3-nit robenzene-1, 2-diol |
| TW201036949A (en) | 2009-02-27 | 2010-10-16 | Lundbeck & Co As H | Treatment of dyskinesia related disorders |
| KR102329271B1 (ko) | 2009-04-01 | 2021-11-22 | 바이알 - 포르텔라 앤드 씨에이 에스에이 | 니트로카테콜 유도체를 포함하는 제약 제제 및 그의 제조 방법 |
| US8492538B1 (en) * | 2009-06-04 | 2013-07-23 | Jose R. Matos | Cyclodextrin derivative salts |
| WO2011034217A1 (ja) * | 2009-09-18 | 2011-03-24 | 株式会社Ｒｉｖｅｒｓｏｎ | ポリフェノール誘導体及びそれの産生方法 |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| PL2791134T3 (pl) | 2011-12-13 | 2020-03-31 | BIAL - PORTELA & Cª S.A. | Związek chemiczny użyteczny jako związek pośredni do wytwarzania inhibitora katechol-o-metylotransferazy |
| RU2017120184A (ru) | 2014-11-28 | 2018-12-28 | БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. | Лекарства для замедления течения болезни паркинсона |
| TWI816716B (zh) | 2017-11-24 | 2023-10-01 | 丹麥商Ｈ 朗德貝克公司 | 用於治療帕金森病之新兒茶酚胺前驅藥 |
| US11168056B2 (en) | 2019-05-20 | 2021-11-09 | H. Lundbeck A/S | Process for the manufacturing of (6aR,10aR)-7-propyl-6,6a,7,8,9,10,10a,11-octahydro-[1,3]dioxolo[4′,5′:5,6]benzo[1,2-G]quinoline and (4aR,10aR)-1-propyl-1,2,3,4,4a,5,10,10a-octahydro-benzo[G]quinoline-6,7-diol |
| US11111263B2 (en) | 2019-05-20 | 2021-09-07 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4a,5,10,10a-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11104697B2 (en) | 2019-05-20 | 2021-08-31 | H. Lundbeck A/S | Process for the manufacture of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4AR,10AR)-7-hydroxy-1- propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| US11130775B2 (en) | 2019-05-20 | 2021-09-28 | H. Lundbeck A/S | Solid forms of (2S,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(((4aR,10aR)-7-hydroxy-1-propyl-1,2,3,4,4A,5,10,10A-octahydrobenzo[g]quinolin-6-yl)oxy)tetrahydro-2H-pyran-2-carboxylic acid |
| EP3972959A1 (en) | 2019-05-21 | 2022-03-30 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
| US12384765B2 (en) | 2019-05-21 | 2025-08-12 | H. Lundbeck A/S | Catecholamine prodrugs for use in the treatment of Parkinson's Disease |
| US12319710B2 (en) | 2019-05-21 | 2025-06-03 | H. Lundbeck A/S | Catecholamine prodrugs for use in the treatment of Parkinson's diseases |
| CN113727712B (zh) | 2019-05-21 | 2024-11-15 | H.隆德贝克有限公司 | 用于治疗帕金森病的儿茶酚胺氨基甲酸酯前药 |
| EP4247793A1 (en) | 2020-11-17 | 2023-09-27 | H. Lundbeck A/S | New catecholamine prodrugs for use in the treatment of parkinson's disease |
| KR20250006218A (ko) | 2022-04-25 | 2025-01-10 | 인터그레이티브 리서치 래버러토리즈 스웨덴 에이비 | 1,2,3,4,4a,5,6,7,8,9,10,10a-도데카하이드로벤조[G]퀴놀린-6-올 화합물의 신규 에스테르 및 이의 용도 |
| JP2025514341A (ja) | 2022-04-25 | 2025-05-02 | インテグレーティブ リサーチ ラボラトリーズ スウェーデン アーベー | 新規１，２，３，４，４ａ，５，６，７，８，９，１０，１０ａ－ドデカヒドロベンゾ［Ｇ］キノリン－６－オール化合物及びその使用 |
| WO2023208867A1 (en) | 2022-04-25 | 2023-11-02 | Integrative Research Laboratories Sweden Ab | NOVEL 1,2,3,4,4a,5,8,9,10,10a-DECAHYDROBENZO[G]QUINOLIN-6(7H)-ONE COMPOUNDS AND USES THEREOF |
| WO2025078574A1 (en) | 2023-10-12 | 2025-04-17 | Integrative Research Laboratories Sweden Ab | NOVEL ESTERS OF 1,2,3,4,4a,5,6,7,8,9,10,10a-DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF |
| WO2025078571A1 (en) | 2023-10-12 | 2025-04-17 | Integrative Research Laboratories Sweden Ab | NOVEL CARBONATES AND CARBAMATES OF 1,2,3,4,4a,5,6,7,8,9,10,10a- DODECAHYDROBENZO[g]QUINOLIN-6-OL COMPOUNDS AND USES THEREOF |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR1179954A (fr) * | 1956-02-11 | 1959-05-29 | Rhone Poulenc Sa | -1 cyclohexène-1 ones-3 nu-disubstituées, leurs dérivés et leur préparation |
| US3991207A (en) * | 1971-03-18 | 1976-11-09 | Pfizer Inc. | Combination therapy for Parkinson's disease |
| GB1593888A (en) | 1977-12-22 | 1981-07-22 | Wyeth John & Brother Ltd | Hexahydroazepine piperidine and pyrrolidine derivatives |
| DE3062971D1 (en) * | 1979-09-14 | 1983-06-09 | Sandoz Ag | Derivatives of tetraline, their preparation and medicaments containing these compounds |
| ZA805648B (en) * | 1979-09-14 | 1982-04-28 | Sandoz Ltd | Tetraline derivatives, their production and pharmaceutical compositions containing them |
| LU88619I2 (fr) * | 1981-10-16 | 1995-07-10 | Sandoz Ag | QUINAGOLIDE, éventuellement sous forme de sel, par exemple du chlorhydrate |
| CA2065450A1 (en) * | 1989-07-05 | 1991-01-06 | James V. Peck | Substituted 2-aminotetralins |
| EP0641320B1 (en) * | 1991-04-17 | 2001-05-30 | PHARMACIA & UPJOHN COMPANY | Substituted (s)-3-phenylpiperidine derivatives, their preparation and their use as dopamine autoreceptor antagonists |
| DE4114325A1 (de) | 1991-05-02 | 1992-11-05 | Sandoz Ag | Octahydrobenzo(g)chinolin, seine herstellung und verwendung |
| GB2260980A (en) * | 1991-10-31 | 1993-05-05 | Shell Int Research | Preparation of unsaturated cyclic ketones |
| GB9326010D0 (en) * | 1993-12-21 | 1994-02-23 | Sandoz Ltd | Improvements in or relating to organic compounds |
| CA2267315C (en) * | 1997-08-07 | 2008-01-08 | Fujimoto Brothers Co., Ltd. | Ethylamine derivatives |
| AU4413999A (en) * | 1998-07-28 | 2000-02-21 | Warner-Lambert Company | Hexahydro-naphthalenone oximes and hydrazones |
| SV2001000202A (es) * | 1999-10-20 | 2001-10-16 | Warner Lambert Co | Uso de (-)-5-ceto-2-n,n-d1-n-propilamino-tetrahidrotetralina para el tratamiento del mal de parkinson |
-
2000
- 2000-04-18 SE SE0001438A patent/SE0001438D0/xx unknown
-
2001
- 2001-04-17 CA CA002406044A patent/CA2406044C/en not_active Expired - Fee Related
- 2001-04-17 ES ES01922208T patent/ES2244604T3/es not_active Expired - Lifetime
- 2001-04-17 NZ NZ521860A patent/NZ521860A/en not_active IP Right Cessation
- 2001-04-17 DE DE60112269T patent/DE60112269T2/de not_active Expired - Lifetime
- 2001-04-17 AT AT01922208T patent/ATE300290T1/de active
- 2001-04-17 AU AU2001248982A patent/AU2001248982B2/en not_active Ceased
- 2001-04-17 PT PT01922208T patent/PT1274411E/pt unknown
- 2001-04-17 WO PCT/SE2001/000840 patent/WO2001078713A1/en not_active Ceased
- 2001-04-17 JP JP2001576014A patent/JP4819280B2/ja not_active Expired - Fee Related
- 2001-04-17 HU HU0300543A patent/HU229794B1/hu not_active IP Right Cessation
- 2001-04-17 US US10/258,014 patent/US6683087B2/en not_active Expired - Fee Related
- 2001-04-17 CN CNB2005101253198A patent/CN100383126C/zh not_active Expired - Fee Related
- 2001-04-17 AU AU4898201A patent/AU4898201A/xx active Pending
- 2001-04-17 CZ CZ20023455A patent/CZ20023455A3/cs unknown
- 2001-04-17 CN CNB018082858A patent/CN1234351C/zh not_active Expired - Fee Related
- 2001-04-17 DK DK01922208T patent/DK1274411T3/da active
- 2001-04-17 PL PL365113A patent/PL204661B1/pl unknown
- 2001-04-17 EP EP01922208A patent/EP1274411B1/en not_active Expired - Lifetime
- 2001-04-17 SI SI200130409T patent/SI1274411T1/sl unknown
-
2002
- 2002-10-02 ZA ZA200207919A patent/ZA200207919B/xx unknown
-
2003
- 2003-12-18 US US10/737,782 patent/US6998405B2/en not_active Ceased
-
2007
- 2007-04-25 US US11/790,465 patent/USRE42802E1/en not_active Expired - Fee Related
-
2010
- 2010-11-12 US US12/945,057 patent/USRE43244E1/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200207919B (en) | Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use. | |
| ES2898315T3 (es) | Preparación de nicotina racémica mediante reacción de nicotinato de etilo con n-vinilpirrolidona en presencia de una base de alcoholato y etapas de proceso posteriores | |
| IL146582A0 (en) | Novel compounds, their use and preparation | |
| BG107120A (bg) | Нови бавнодействащи бетамиметици, метод за тяхното получаване и приложението им като лекарствени средства | |
| HUP0004040A1 (hu) | Antimikrobiális hatású pleuromutilinszármazékok, eljárás ezek előállítására, ezeket tartalmazó gyógyászati készítmények és alkalmazásuk | |
| WO2001081308A3 (en) | Aminopiperidines for use as glyt-1 inhibitors | |
| TWI265928B (en) | A61k 31/4025 200601 a i htw a61p 25/00 200601 a n htw | |
| MXPA02012875A (es) | Derivado de benzoilpiridina o su sal, fungicida que lo contiene como un ingrediente activo, su procedimiento de produccion e intermediario para producirlo. | |
| IL148975A0 (en) | Novel cyclopropanes as cprp antagonists, medicaments containing said compounds and method for the production thereof | |
| HU9400132D0 (en) | Tricyclic condensed heterocyclic compounds, process for producing them and pharmaceutical compositions contaning them as active component | |
| WO2009044018A9 (fr) | Dérivés de 1-0x0-1,2-dihydroisoquinoleine-5-carboxamides et de 4-oxo-3,4-dihydroquinazoline-8-carboxamides, leur préparation et leur application en thérapeutique | |
| WO2008059130A9 (fr) | Thionucléosides et applications pharmaceutiques | |
| EP0567090A3 (enExample) | ||
| SG54269A1 (en) | Substituted benzothienylpiperazines their use as medicaments and processes for their preparation | |
| PL358015A1 (en) | Thienopyridine derivatives and their use as anti-inflammatory agents | |
| US3655737A (en) | 1-(3-hydroxy-4-methyl-phenyl)-propylamine (-2) and the salts thereof | |
| JP2004502773A5 (enExample) | ||
| KR930017874A (ko) | 포화 질소 헤테로사이클의 유도체 | |
| TW200728272A (en) | Compound and method for manufacturing the same, positive resist composition and method for forming resist pattern | |
| Battisthi et al. | High stereoselectivity in the formation of the inter-ribonucleotidic phosphorothioate bond | |
| CA2544649A1 (en) | Morpholine derivatives as norepinephrine reuptake inhibitors | |
| MY139608A (en) | Thieno-(1,3)-oxazin-4-ones with lipase inhibiting activity | |
| WO1998049165B1 (en) | CYTOTOXIC COMPOUNDS: DERIVATIVES OF THE PYRIDO[2,3,4-kl] ACRIDINE RING SYSTEM | |
| NZ789776A (en) | Spiro compound serving as erk inhibitor, and application thereof | |
| TH64995A (th) | ซับสทิทิวเทดพิเพอริดีนชนิดใหม่, สารผสมทางเภสัชกรรมที่มีสารประกอบเหล่านี้, การใช้สารประกอบเหล่านี้และกรรมวิธีสำหรับเตรียมสารประกอบเหล่านี้ |